MX374380B - Composicion inmunógena de clostridium difficile. - Google Patents
Composicion inmunógena de clostridium difficile.Info
- Publication number
- MX374380B MX374380B MX2016017094A MX2016017094A MX374380B MX 374380 B MX374380 B MX 374380B MX 2016017094 A MX2016017094 A MX 2016017094A MX 2016017094 A MX2016017094 A MX 2016017094A MX 374380 B MX374380 B MX 374380B
- Authority
- MX
- Mexico
- Prior art keywords
- clostridium difficile
- protein
- cdtb
- immunogenic composition
- isolated
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a composiciones inmunogénicas que comprende las CDTb Clostridium difficile. En particular, la proteína de CDTb Clostridium difficile aislada se ha mutado para modificar la habilidad de formación de poros, para modificar la habilidad de heptamerización o es una proteína CDTb truncada con el péptido señal y el prodominio eliminado y también se eliminó el dominio de unión al receptor y/o se eliminó el dominio de unión a CDTa. La invención también se refiere a proteínas de fusión que comprenden una proteína CDTa y una proteína CDTb. Las vacunas que comprenden dichas composiciones inmunogénicas y usos terapéuticos de las mismas también forman parte de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016017094A MX2016017094A (es) | 2017-05-03 |
| MX374380B true MX374380B (es) | 2025-03-06 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017094A MX374380B (es) | 2014-06-25 | 2015-06-25 | Composicion inmunógena de clostridium difficile. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (es) |
| EP (2) | EP3160500B1 (es) |
| JP (2) | JP6688233B2 (es) |
| CN (1) | CN106536544B (es) |
| BE (1) | BE1022949B1 (es) |
| BR (1) | BR112016030096B1 (es) |
| CY (1) | CY1122145T1 (es) |
| DK (1) | DK3160500T3 (es) |
| ES (1) | ES2749701T3 (es) |
| HR (1) | HRP20191864T1 (es) |
| HU (1) | HUE045936T2 (es) |
| LT (1) | LT3160500T (es) |
| MX (1) | MX374380B (es) |
| PL (1) | PL3160500T3 (es) |
| PT (1) | PT3160500T (es) |
| SI (1) | SI3160500T1 (es) |
| WO (1) | WO2015197737A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170238A2 (en) * | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| BR112020024514A2 (pt) | 2018-06-19 | 2021-03-02 | Glaxosmithkline Biologicals S.A. | composição imunogênica |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| AU709586B2 (en) | 1994-10-24 | 1999-09-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JPH11506332A (ja) | 1995-06-02 | 1999-06-08 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 全長ｃＤＮＡ配列を獲得する改良された方法 |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| AU2003304316A1 (en) * | 2002-11-08 | 2005-01-28 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| KR20140101835A (ko) * | 2011-12-08 | 2014-08-20 | 노파르티스 아게 | 클로스트리듐 디피실레 톡신-기반 백신 |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| ES2939307T3 (es) * | 2012-12-05 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Composición inmunogénica |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3160500T3 (da) | 2019-11-11 |
| BR112016030096B1 (pt) | 2023-10-03 |
| SI3160500T1 (sl) | 2019-11-29 |
| WO2015197737A1 (en) | 2015-12-30 |
| MX2016017094A (es) | 2017-05-03 |
| JP6688233B2 (ja) | 2020-04-28 |
| PT3160500T (pt) | 2019-11-11 |
| PL3160500T3 (pl) | 2020-02-28 |
| CY1122145T1 (el) | 2020-11-25 |
| BE1022949B1 (fr) | 2016-10-21 |
| BR112016030096A8 (pt) | 2021-07-06 |
| EP3160500B1 (en) | 2019-08-21 |
| JP2020100625A (ja) | 2020-07-02 |
| EP3636278A3 (en) | 2020-07-15 |
| HUE045936T2 (hu) | 2020-01-28 |
| BR112016030096A2 (pt) | 2017-08-22 |
| HRP20191864T1 (hr) | 2020-01-10 |
| BE1022949A1 (fr) | 2016-10-21 |
| LT3160500T (lt) | 2019-10-25 |
| JP2017520573A (ja) | 2017-07-27 |
| CN106536544B (zh) | 2020-04-07 |
| EP3160500A1 (en) | 2017-05-03 |
| EP3636278A2 (en) | 2020-04-15 |
| CN106536544A (zh) | 2017-03-22 |
| ES2749701T3 (es) | 2020-03-23 |
| CA2952118A1 (en) | 2015-12-30 |
| US20170218031A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| EP3155018A4 (en) | Constant region antibody fusion proteins and compositions thereof | |
| EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
| MX363533B (es) | Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas. | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| EA201691429A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
| IL275435B (en) | tatk-cdkl5 fusion proteins, preparations, formulations, and their uses | |
| MX2017001038A (es) | Variantes de proteina de unión al factor h y metodos de uso de estas. | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| EA202091567A1 (ru) | Химерные белки мти | |
| EP3125923A4 (en) | Lyophilized pharmaceutical composition of fc-peptide fusion protein | |
| PH12017502277A1 (en) | Multi-specific binding proteins | |
| CY1122145T1 (el) | Ανοσογονικη συνθεση για clostridium difficile | |
| WO2018119312A8 (en) | Methods and formulations for reducing reconstitution time of lyophilized polypeptides | |
| EP4512469A3 (en) | Binding proteins to the human thrombin receptor, par4 | |
| WO2014152831A3 (en) | Targeting peptides and uses thereof | |
| MX2021006543A (es) | Vacuna. | |
| WO2014152271A8 (en) | Viral proteins as immunomodulatory agents and vaccine components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |